<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00497315</url>
  </required_header>
  <id_info>
    <org_study_id>TOGA 0502</org_study_id>
    <secondary_id>Eudra CT 2005-004030-40</secondary_id>
    <nct_id>NCT00497315</nct_id>
  </id_info>
  <brief_title>Evaluation of Pemetrexed Combined With Cisplatin and Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <acronym>PACCORA</acronym>
  <official_title>A Randomized Multicenter Phase II Study Of Induction Therapy With Pemetrexed And Cisplatin Followed By Chemoradiation With Pemetrexed Versus Chemoradiation With Pemetrexed Followed By Consolidation Therapy With Pemetrexed And Cisplatin In Patients With Stage III Non-Small Cell Lung Cancer: Paccora Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universiteit Antwerpen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate if the multi modality treatment pemetrexed combined with
      cisplatin and radiotherapy can lead to a better tumor control and/or a better side-effect
      profile in patients with locally advanced NSCLC. Patients will be randomized between 3 cycles
      of induction chemotherapy followed by concurrent chemoradiotherapy or concurrent
      chemoradiotherapy followed by 3 cycles of adjuvant combination chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>after each treatment modality and 5 year follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>at the end of each cycle and 5 year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>5 year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>median survival and 2-year survival</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pemetrexed + cisplatin (3 cycles) followed by thoracic irradiation + pemetrexed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>thoracic irradiation + pemetrexed followed by pemetrexed + cisplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>combination chemotherapy (pemetrexed + cisplatin)</intervention_name>
    <description>pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 (q 3 weeks for 3 cycles)</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Alimta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>thoracic irradiation + pemetrexed</intervention_name>
    <description>pemetrexed 500 mg/m2 (q 3weeks for 2 cycles), 60 GY (30 fractions of 2 GY)</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Alimta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  cytological or histological proven NSCLC

          -  unresectable stage III NSCLC

          -  presence of at least one measurable lesion (RECIST criteria)

          -  adequate haematological, renal and hepatic function

          -  adequate lung function reserve

          -  good condition, weight loss &lt;10 % over previous 6 months, life expectancy &gt; 3 months

        Exclusion Criteria:

          -  previous chemo- or radiotherapy for NSCLC

          -  distant metastasis or a malignant pleural or pericardial effusion

          -  second active primary malignancy or serious concomitant medical disease

          -  interstitial lung disease

          -  auto-immune systemic disease with potential involvement of the lungs

          -  inability to interrupt aspirin or other non-steroidal anti-inflammatory agents for a
             5-day period

          -  concomitant use of amiodarone
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul R Germonpre, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universiteit Antwerpen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ZNA Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <state>Antwerp</state>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Antwerp</name>
      <address>
        <city>Edegem</city>
        <state>Antwerp</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Augustinus Ziekenhuis</name>
      <address>
        <city>Wilrijk</city>
        <state>Antwerp</state>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 4, 2007</study_first_submitted>
  <study_first_submitted_qc>July 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2007</study_first_posted>
  <last_update_submitted>April 9, 2009</last_update_submitted>
  <last_update_submitted_qc>April 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2009</last_update_posted>
  <responsible_party>
    <name_title>Thoracic Oncology Group Antwerp - Paul Germonpre</name_title>
    <organization>Thoracic Oncology Group Antwerp</organization>
  </responsible_party>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Chemoradiation</keyword>
  <keyword>locally advanced NSCLC</keyword>
  <keyword>pemetrexed</keyword>
  <keyword>lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

